Advent France Biotechnology (AFB), an AMF-regulated investment company dedicated to life sciences, is changing its company name to AdBio partners.
The name change reflects the company’s expansion beyond France with UK-based partner Advent Life Sciences.
AdBio Partners held the first close of its second fund at EUR86 million (USD102 million) in September 2021. This fund will be used to create, develop and finance European life sciences start-ups, with the goal of selecting and financing two before the end of 2021. second fund is larger than the first seed fund launched in 2017, which closed at EUR68 million.
